Company News
A Naturally Occurring Peptide May Offer a New Approach to Multiple Neurodegenerative Diseases
Researchers at UC San Diego found that catestatin, a peptide naturally produced by the body, reduced signs of neurodegeneration in mice. Here is what these early findings could mean for future brain health research.
Alzheimer’s disease and other neurodegenerative conditions share a troubling feature: changes in the brain can begin years before symptoms become noticeable. Researchers are looking for treatments that could target several processes involved in these diseases rather than focusing on just one. A new study from UC San Diego, published in Molecular Therapy, offers an early look at one possible approach.
The research team, led by Sushil K. Mahata and colleagues at UC San Diego and the VA San Diego Healthcare System, studied catestatin (CST). This small peptide is naturally produced by the body from a larger protein called chromogranin A. In mouse models of neurodegeneration, catestatin reduced the buildup of tau tangles and amyloid plaques, two abnormal protein deposits associated with Alzheimer’s disease. The researchers also observed lower levels of markers linked to brain inflammation, along with improvements in the animals’ memory-related abilities and movement.
One reason this finding has attracted interest is that catestatin appeared to affect several processes linked to neurodegeneration at the same time. Many experimental treatments focus on a single biological target, but these diseases involve multiple interacting mechanisms. An approach that influences several of these processes could offer a different direction for future research.
The researchers suggest that catestatin may work partly by regulating adrenergic signaling, a system involved in the body’s response to stress. This signaling can influence processes in the brain related to inflammation and the buildup of harmful proteins. Understanding how catestatin affects these pathways could help researchers investigate new ways to address neurodegenerative diseases.
However, the findings are still at an early stage. The research was conducted in animal models, and results in mice do not necessarily translate to people. Researchers still need to establish whether catestatin is safe and effective in humans, determine appropriate doses, and better understand how it works before it can be considered as a potential treatment.
For adults concerned about memory changes, cognitive health, or a family history of neurodegenerative disease, speaking with a board-certified physician is a useful first step. A physician can help assess individual risk factors, discuss current evidence, and recommend appropriate screening or follow-up when needed.
References
Newswise. Naturally Occurring Peptide May Offer New Approach to Neurodegeneration. Newswise.com.
Neuroscience News. Can a Natural Peptide Tackle Multiple Drivers of Alzheimer’s at Once? NeuroscienceNews.com.
PubMed Central. Catestatin Ameliorates Tauopathy and Amyloidogenesis via Adrenergic Inhibition. NIH.gov.
Alzheimer’s Association. What Is Alzheimer’s Disease? Alzheimer’s Association.